GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (FRA:A28A) » Definitions » Cyclically Adjusted PS Ratio

Affimed NV (FRA:A28A) Cyclically Adjusted PS Ratio : 2.36 (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Cyclically Adjusted PS Ratio?

As of today (2024-06-09), Affimed NV's current share price is €5.72. Affimed NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €2.42. Affimed NV's Cyclically Adjusted PS Ratio for today is 2.36.

The historical rank and industry rank for Affimed NV's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:A28A' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.91   Med: 1.9   Max: 6.52
Current: 1.94

During the past years, Affimed NV's highest Cyclically Adjusted PS Ratio was 6.52. The lowest was 0.91. And the median was 1.90.

FRA:A28A's Cyclically Adjusted PS Ratio is ranked better than
74.01% of 504 companies
in the Biotechnology industry
Industry Median: 5.47 vs FRA:A28A: 1.94

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Affimed NV's adjusted revenue per share data for the three months ended in Dec. 2023 was €0.028. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €2.42 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Affimed NV Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Affimed NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Cyclically Adjusted PS Ratio Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.71 1.97

Affimed NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.71 2.16 1.72 1.36 1.97

Competitive Comparison of Affimed NV's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Affimed NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affimed NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Affimed NV's Cyclically Adjusted PS Ratio falls into.



Affimed NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Affimed NV's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=5.72/2.42
=2.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affimed NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Affimed NV's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.028/123.7729*123.7729
=0.028

Current CPI (Dec. 2023) = 123.7729.

Affimed NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.301 99.543 0.374
201406 0.309 99.543 0.384
201409 0.789 99.823 0.978
201412 0.034 99.543 0.042
201503 1.026 99.717 1.274
201506 0.810 100.417 0.998
201509 0.380 100.417 0.468
201512 0.497 99.717 0.617
201603 0.572 100.017 0.708
201606 0.618 100.717 0.759
201609 0.282 101.017 0.346
201612 0.406 101.217 0.496
201703 0.098 101.417 0.120
201706 0.115 102.117 0.139
201709 0.104 102.717 0.125
201712 0.141 102.617 0.170
201803 0.097 102.917 0.117
201806 0.024 104.017 0.029
201809 0.049 104.718 0.058
201812 3.644 104.217 4.328
201903 1.819 104.217 2.160
201906 0.642 105.718 0.752
201909 0.337 106.018 0.393
201912 0.515 105.818 0.602
202003 0.673 105.718 0.788
202006 0.371 106.618 0.431
202009 1.226 105.818 1.434
202012 1.055 105.518 1.238
202103 1.003 107.518 1.155
202106 0.811 108.486 0.925
202109 0.723 109.435 0.818
202112 0.845 110.384 0.947
202203 0.649 113.968 0.705
202206 0.496 115.760 0.530
202209 0.997 118.818 1.039
202212 0.747 119.345 0.775
202303 0.302 122.402 0.305
202306 0.093 123.140 0.093
202309 0.131 124.195 0.131
202312 0.028 123.773 0.028

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Affimed NV  (FRA:A28A) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Affimed NV Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Affimed NV's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Affimed NV (FRA:A28A) Business Description

Industry
Traded in Other Exchanges
Address
Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Affimed NV (FRA:A28A) Headlines

No Headlines